RxDoctor Payments Data

Farah Masood, MD

Internal Medicine · Sunnyvale, TXNPI 1447403563

Payments from drug & device makers

$5,069in general payments, 2019–2025

Across 113 payments — averaging $44.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Philips North America LLC$959
  • AstraZeneca$860
  • E.r. Squibb & Sons, L.L.C.$387
  • Smith+Nephew$279
  • Medtronic$157
  • plus $1K from 22 others

What the payments were for

  • Travel & lodging$95919%
  • Food & beverage$4,11181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,069 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$275,950
Medicare patients
796
Services billed
2,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$31,722
FarxigaDapagliflozin Propanediol35$25,334
JardianceEmpagliflozin26$21,399
MounjaroTirzepatide20$20,786
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen123$3,085
Gabapentin121$1,625
Linezolid14$1,203
Gentamicin Sulfate40$1,033
Doxycycline Monohydrate55$940
Albuterol Sulfate HfaAlbuterol Sulfate30$834
Metronidazole15$750
Atorvastatin Calcium94$699
Levothyroxine Sodium52$502
Potassium Chloride34$493
Cefdinir35$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$31,72234 claims
AstraZenecaFarxiga$860$25,33435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Sunnyvale

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →